Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Medivation Inc    MDVN

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Medivation Inc : MDVN, OXBT, PTIE and SYMM added to NASDAQ Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/23/2013 | 03:30pm CET

New York, NY - (ACCESSWIRE) - 10/23/2013 - Equity Profile Report initiates its NASDAQ Gainers Watch List adding Medivation, Inc. (NASDAQ:MDVN), Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), Pain Therapeutics Inc. (NASDAQ:PTIE), and Symmetricom Inc. (NASDAQ:SYMM)

Medivation, Inc. (NASDAQ:MDVN) a biopharmaceutical company that focuses on development and commercialization of novel therapies to treat serious diseases in the United States is currently up (+8.17%) on 4,286,602 shares traded after Medivation and Astellas Announced the Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naive Patients With Advanced Prostate Cancer. Medivation, Inc. (NASDAQ:MDVN) is currently up (+28.65%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Medivation, Inc. (NASDAQ:MDVN)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=MDVN&SubId=AW

Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) a development stage company that engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States is currently up (+30.00%) on 6,172,456 shares traded after Oxygen Biotherapeutics Signed Agreement to Acquire Phase 3, FDA Fast Track Product to Pursue Potential $600 Million Cardiovascular Market. Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) is currently up (+52.94%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=OXBT&SubId=AW

Pain Therapeutics Inc. (NASDAQ:PTIE) a biopharmaceutical company that develops novel drugs is currently up (+16.00%) on 2,154,392 shares traded after Pain Therapeutics Reported that Pfizer Elects to Continue Development of REMOXY. Pain Therapeutics Inc. (NASDAQ:PTIE) is currently up (+75.35%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Pain Therapeutics Inc. (NASDAQ:PTIE)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=PTIE&SubId=AW

Symmetricom Inc. (NASDAQ:SYMM) a company that provides timekeeping technologies, instruments, and solutions worldwide is currently up (+51.15%) on 16,220,860 shares traded after Symmetricom Reported its First Quarter Fiscal Year 2014 Financial Results. Symmetricom Inc. (NASDAQ:SYMM) is currently up (+66.13%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Gainers Watch List and Investor Poll.

To find out what other Investors are saying about Symmetricom Inc. (NASDAQ:SYMM)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=SYMM&SubId=AW

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed.

Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.equityprofilereport.com/

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures.

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MEDIVATION INC
10/28 Drugmaker Sanofi hungry for deals after earnings beat
10/09 MEDIVATION : New Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼..
10/06 PFIZER : Completes Acquisition of Medivation
09/28 MEDIVATION, INC. : Termination of a Material Definitive Agreement, Completion of..
09/28 PFIZER INC. (NYSE : PFE) Acquisition Of Medivation, Inc. (NASDAQ:MDVN) To Close ..
09/28 Xenon Pharmaceuticals Appoints Dawn Svoronos to Its Board of Directors
09/28 MEDIVATION : Highlights New Data From Differentiated Oncology Portfolio at ESMO ..
09/26 PFIZER : Announces Expiration of HSR Waiting Period For Proposed Acquisition of ..
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/23 PFIZER : expects to close Medivation buyout in 3Q
More news
Sector news : Bio Therapeutic Drugs
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
10/18 M&A Gives Signs Of Reverting To The Mean
10/12 Pfizer's Growth Strategies May Need More Than Just Small Acquisitions
10/10 Lively M&A Scene Keeps Biotech Shares Buoyant In Q3
10/08 MARKETPLACE ROUNDTABLE : Sifting The World And The M&A Market
10/05 Global M&A Drops In 3rd Quarter, Companies Wary Of Overpaying
Advertisement
Financials ($)
More Financials
Chart MEDIVATION INC
Duration : Period :
Medivation Inc Technical Analysis Chart | MDVN | US58501N1019 | 4-Traders
Full-screen chart
Technical analysis trends MEDIVATION INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
David T. Hung Chief Executive Officer & Director
Douglas E. Giordano President, Director & Treasurer
Marion McCourt Chief Operating Officer
Jennifer Jarrett Chief Financial Officer
Mohammad Hirmand Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDIVATION INC68.47%0
AMGEN, INC.-11.25%105 927
GILEAD SCIENCES, INC.-27.17%95 964
CELGENE CORPORATION-0.74%92 148
REGENERON PHARMACEUTIC..-30.82%39 610
ACTELION LTD40.40%20 855
More Results